Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial -

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers
Summary
After a median follow-up of 12.2 months, cediranib did not improve progression-free survival in patients (n=124) with advanced biliary tract cancer in combination with cisplatin and gemcitabine (8.0 months v 7.4 months respectively, p=0.72) which remains the standard of care.
UKMi comment
Cediranib currently holds “Orphan Drug” status in the EU for the treatment of ovarian cancer.
Related links: Editorial